Психические расстройства в общей медицине. №1 2011

Генерализованное тревожное расстройство: эпидемиология, патогенез, диагностика и фармакотерапия (обзор литературы)

Д.Ю.Вельтищев, А.С.Марченко

ФГУ Московский НИИ психиатрии Минздравсоцразвития РФ

Стр. 56-63

2639 просмотров

Опубликовано: 1 января 2011

Аннотация / Abstract

Резюме. В статье представлен обзор современных публикаций, посвященных эпидемиологии, патогенезу, диагностическим критериям, коморбидности и лечению генерализованного тревожного расстройства. Это расстройство широко распространено в популяции и среди пациентов общей медицинской практики, приводит к существенной дезадаптации и ухудшению соматического здоровья. Однако выделение специфичных диагностических критериев генерализованного тревожного расстройства, а также обоснование его самостоятельности вне других расстройств, прежде всего депрессивных, по-прежнему актуально. Приводится анализ отдельных аспектов проблемы с акцентом на патогенетически обоснованных подходах к фармакотерапии генерализованного тревожного расстройства. Ключевые слова: генерализованное тревожное расстройство, эпидемиология, патогенез, диагностика, фармакотерапия, прегабалин. Generalized anxiety disorder: epidemiology, pathogenesis, diagnosis and pharmacotherapy (review article) D.Yu.Veltishchev, A.S.Marchenko Moscow Research Institute of Psychiatry, Ministry of Health and Social Development of the Russian Federation Summary. The paper reviews current publications on the epidemiology, pathogenesis, diagnostic criteria, comorbidity, and treatment of generalized anxiety disorder. The latter is widely spread in the population and general medical practice patients and results in substantial disadaptation and worse somatic health. However, to identify specific diagnostic criteria for generalized anxiety disorder and to substantiate its independence outside other disorders, mainly depressive ones, are urgent as before. Some aspects of the problem are analyzed with emphasis on pathogenetically based approaches to pharmacotherapy for generalized anxiety disorder. Key words: generalized anxiety disorder, epidemiology, pathogenesis, diagnosis, pharmacotherapy, pregabalin. Генерализованное тревожное расстройство (ГТР) выделено из группы тр...

Материал для специалистов

Полный текст статьи доступен только зарегистрированным пользователям.

Вход / Регистрация

1. Вертоградова О.П., Поляков С.Э., Степанов И.Л. и др. Распространенность и характеристика аффективных расстройств, выявленных при эпидемиологическом исследовании лиц работоспособного возраста. В кн.: Ранняя диагностика и прогноз депрессий. М.: МНИИП, 1990; с. 5–15.
2. Abelson JL. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 1991; 48: 157–62.
3. Akiskal HS. Toward a definition of generalized anxiety disorder as an anxious temperament type. Acta Psychiatr Scand 1998; 98 (Suppl. 3): 66–73.
4. American Psychiatric Association DSM-V Development, 2010, dsm5.org
5. Andlin-Sobocki P, Wittchen H. Cost of anxiety disorders in Europe. Eur J Neurol 2005; 12 (Suppl.): 39–44.
6. Angst J, Vollrath M. The natural history of anxiety disorders. Acta Psychiatr Scand 1991; 84: 446–52.
7. Angst J, Gamma A, Baldwin DS et al. The generalized anxiety spectrum: prevalence, onset, course and outcome. Eur Arch Psychiatry Clin Neurosci 2009; 259 (1): 37–45.
8. Angst J, Gamma A, Bienvenu JO et al. Varying temporal criteria for generalized anxiety disorder: prevalence and clinical characteristics in a young age cohort. Psychol Med 2006; 36 (9): 1283–92.
9. Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001; 62 (Suppl. 11): 53–8.
10. Blazer DG, Hughes D, George L et al. Generalized anxiety disorder. In Robins, Regier eds. Psychiatric disorders in America. NY: The Free Press 1991: 180–203.
11. Bleakle S. Anxiety disorders – the pharmacological management. Hospital Pharmacist 2006; 13: 119–22.
12. Boden JM, Fergusson DM, Horwood L. Anxiety disorders and suicidal behaviors in adolescence and young adulthood: findings from a longitudinal study. Psychol Med 2007; 62: 1249–57.
13. Britton N, Southreland S, Van Uden E et al. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacol 1997; 132: 6–13.
14. Bruce SE, Yonkers KA, Otto MW et al. Influence of psychiatric comorbidity on recovery and recurrence of GAD. Am J Psychiatry 2005; 162: 1179–87.
15. Bystritsky A, Kerwin L, Feusner JD et al. A pilot controlled trial of bupropion versus escitalopram in GAD. Psychophamacol Bull 2008; 41 (1): 46–51.
16. Carter C, Maddock R. Chest pain in generalized anxiety disorder. Int J Psychiatr 1992; 22: 291–8.
17. Davidson JR. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatr 2009; 70 (2): 25–31.
18. Davidson JR, Zhang W, Connor KM. A psychopharmacological treatment algorithm for generalized anxiety disorder (GAD). J Psychopharmacol 2010; 24: 3.
19. Drugan RC, Skolnick P, Paul S et al. A pretest procedure reliably predicts performance in models of inescapable stress. Pharmacol Biochem Behav 1989; 33: 649–54.
20. Feltner et al. Long term efficacy of pregabalin in generalized anxiety disorder. Inter Clin Phsychopharmacol 2008; 23 (1): 18–28.
21. Ferrarese C, Appolonio I, Frigo M et al. Decreased density of benzodiazepine receptors in lymphocytes of anxious patients. Acta Psychiatr Scand 1990; 82: 69–173.
22. Fischler B, Cluydts R, De Gucht V et al. Generalized anxiety disorder in chronic fatigue syndrome. Acta Psychiatr Scand 1997; 95: 405–13.
23. Gambi F, DeBerardis D. Mirtazapine treatment of GAD: a fixed dose, open label study. J Psychopharmacol 2005; 19 (5): 483–7.
24. Garvey MJ, Noyes R, Woodman C et al. Relationship of generalized anxiety symptoms to urinary 5-hydroxyindoleacetic acid and vanillymandelic acid. Psychiatry Res 1995; 57: 1–5.
25. Goodman WK, Bose A, Wang O. Treatment of GAD with escitalopram: pooled resulys J Affect Dis 2005; 87 (2–3): 161–7.
26. Grant BF, Hasin DS, Stinson FS et al. Prevalence, correlates, comorbidity and comparative disability of DSM-IV GAD in the USA: results from the National Comorbidity Survey Psychol Med 2005; 35 (12): 747–59.
27. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Therapy 1999; 82: 1–61.28. Harter M, Conway KP, Merinkangas KR. Associations between anxiety disorders and physical illness. Eur Arch Psychiatry Clin Neurosci 2003; 253: 313–20.
29. Hedges DW, Reimherr FW, Strong RE et al. An open trial of nefazadone in adult patients with GAD. Psychopharmacol Bull 1996; 32 (4): 671–6.
30. Hindmarch I, Dawson J, Stanley N. Evaluation of the cognitive and psychomotor profile of pregabalin compared to alprazolam in normal volunteers. Int J Neuropsychopharmacol 2002; 5 (1): 241.
31. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alpazolam and placebo. Sleep 2005; 28: 187–93.
32. Ноffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depres anxiety 2006; 10: 1–19.
33. Hunt C, Slade T, Andrews G. GAD and major depression comorbidity in the National Survey. Depres Anxiety 2004; 20 (1): 23–31.
34. Jetty PV, Charney DS, Goodard AW. Neurobiology of generalized anxiety disorder. Psychiatr Clin North Am 2001; 24: 75–98.
35. Judd LL, Kessler RC, Paulus MP et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study. Acta Psych Scand 1998; 98 (Suppl. 393): 6–11.
36. Kasper et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009; 24: 87–96.
37. Kavoussi R. Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol 2006; 16 (Suppl. 2): 128–133.
38. Kennedy B, Schwab J. Utilization of medical specialists by anxiety disorders patients. Psychosomatics 1997; 38: 109–112.
39. Kennedy JL, Bradwein J, Koszicky D et al. Investigation of cholecystokinin system genes in anxiety disorders. Mol Psychiatr 1999; 4: 284–5.
40. Kessler RC, Brandeburg N, Lane M et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from National Comorbidity Survey Replication. Psycol Med 2005; 35: 1073–82.
41. Kessler RC, DuPont RL, Berglund A et al. Impairment in pure and comorbid GAD and major depression at 12 months in two national surveys. Am J Psychiatr 1999; 156: 1915–23.
42. Kessler RC, Keller MB, Wittchen HU. The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am 2001; 24: 19–39.
43. Kessler RC, Chiu WT, Demler O et al. Prevalence, severity and comorbidity of 12-month DSM-IV disorders in NCSR. Arch Gen Psychiatr 2005; 62: 617–27.
44. Khan A, Farfel GM, Brock JD. Efficacy and safety of pregabalin for the treatment of GAD in elderly patients. Ann Meeting of APA, Toronto 2006; 283–4.
45. Koponen H, Allgulander C, Erickson et al. Efficacy of duloxetine for the treatment of anxiety disorder: implication for primary care. Prim Care Comp. J Clin Psychiatry 2007; 9 (2): 100–7.
46. Krasucki C, Howarf R, Mann A. The relationship between anxiety disorders and age. Int J Geriatr Psychiatry 1998; 13 (2): 79–99.
47. Kroenke K, Spilzer RL, Williams JB et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity and detection. Ann Intern Med 2007; 146: 317–25.
48. Koob GF. Corticotropin-relesing factor, norepinephrine and stress. Biol Psychiatr 1999; 46: 1167–80.
49. Lenze EJ, Mulsant BH, Shear MK et al. Efficacy and tolerability of citalopram in the treatment of late life anxiety disorders. Am J Psychiatry 2005; 162 (1): 146–50.
50. Leon AC, Olfson M, Broadhead WE et al. Prevalence of mental disorders in primary care: implication for screening. Arch Fam Med 1995; 4: 857–61.
51. Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005; 15 (4): 445–52.
52. Llorca PM, Spadone C, Sol O et al. Efficacy and safety of hydroxyzine in the treatment of GAD. J Clin Psychiatr 2002; 63 (11): 1020–27.
53. Lowe B, Decker O, Muller S et al. Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population. Med Care 2008; 46 (3): 266–74.
54. Lydiard B, Bielsky R, Tobias K. The efficacy of pregabalin in treating psychic and somatic symptoms in GAD. Eur Neuropsychopharmacol 2003; 13 (4): 377.
55. Lydiard RB. Neuropeptides and anxiety: focus on cholecystokinin. Clin Chem 1994; 40: 315–18.
56. Mendlewicz J, Papadimitriou G, Wimotte J. Family study of panic disorder: comparison to generalized anxiety disorder, major depression and normal subjects. Psychiatry Genetic 1993; 3: 73–8.
57. Montgomery SA. Pregabalin for the treatment of GAD. Expert Opin Pharmacother 2006; 7 (15): 2139–54.
58. Montgomery SA, Tobias K, Zornberg GL et al. Efficacy and safety of pregabalin in the treatment of GAD: a 6-week multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67 (5): 771–82.
59. Montgomery et al. The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. Int Clin Psychopharmacol 2009; 24: 214–22.
60. Munjack DJ, Baltazar PL, DeQuattro V et al. Generalized anxiety disorder: some biochemical aspects. Psychiatry Res 1990; 32: 35–43.
61. Noyes R, Clarkson C, Crowe RR et al. A family study of generalized anxiety disorder. Am J Psychiatry 1987; 144: 1019–24.
62. Nutt DJ. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 2001; 62 (Suppl. 11): 22–7.
63. Olfson M, Fireman B, Weissman MM et al. Mental disorders and disability among patients in primary care group practice. Am J Psychiatry 1997; 154: 1734–40.
64. Owen RT. Pregabalin: its efficacy, safety and tolerability profile in GAD. Drugs Today 2007; 43 (9): 601–10.
65. Pande AC, Crocatt JG, Feltner DE et al. Pregabalin in GAD: a placebo-controlled study. Am J Psychiatry 2003; 160 (3): 533–40.
66. Pandina GJ, Canuso CM, Turkoz I et al. Adjunctive risperidone in the treatment of GAD. Psychopharmacol Bull 2007; 40 (3): 41–57.
67. Pohl RB, Feltner DE, Fieve RR et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005; 25: 151–8.
68. Pollack MH, Simon NM, Zalta AK. Olanzapine augmentation of fluoxetine for refractory GAD: a placebo controlled study. Biol Psychiatry 2006; 59 (3): 211–15.
69. Rickels K, Downing R, Schweizer E et al. Antidepressants in the treatment of GAD: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50 (11): 884–95.
70. Rickels K, Wiseman K, Norstad N et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982; 43 (12): 81–6.
71. Rickels et al. Pregabalin for the treatment of generalized anxiety disorder. A four week, double-blind, multi-center, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62: 1022–30.
72. Weisberg RB. Overview of generalized anxiety disorder: epidemiology, presentation and course. J Clin Psychiatry 2009; 70 (Suppl. 2): 4–9.
73. Robert LS, Kurt K, Wiliams JBW et al. A brief measure for assembling generalized anxiety disorder. Arh Intern Med 2006; 166: 1092–97.
74. Rocca P, Beoni A, Eva C et al. Peripheral benzodiazepine receptor messenger RNA in GAD. Biol Psychiatry 1998; 43: 81–6.
75. Rocca P, Fonzo V, Scotta M et al. Paroxetine efficacy in the treatment of GAD. Acta Psychiatr Scand 1997; 95 (5): 444–50.
76. Rodrogues BF, Weisberg RB, Pagano ME et al. Characteristics and predictors of full and partial recovery from GAD in primary care patients. J Nerv Ment Dis 2006; 194 (2): 91–7.
77. Rogers MP, White K, Warshaw MG et al. Prevalence of medical illness in patients with anxiety disorders. Int J Psychiatr Med 1994; 24: 83–96.
78. Pollack MH, Zaninelly R, Goddard A et al. Paroxetine in the treatment of generalized anxiety disorder. J Clin Psychiatr 2001; 62 (5): 350–7.
79. Roy-Byrne PP, Wagner A. Primary care perspectives on generalized anxiety disorder. J Clin Psychiatry 2004; 65 (Suppl. 13): 20–6.
80. Rubio G, Lopes-Ibor JJ. Generalized anxiety disorder: a 40-year follow-up study. Acta Psychiatr Scand 2007; 115: 342–59.
81. Rynn M, Russell J, Erickson J et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder. Depres Anxiety 2008; 25 (3): 182–9.
82. Sanderson K, Andrews G. Prevalence and severity of mental health-related disability and relation to diagnosis. Psychiatr Serv 2002; 53 (1): 80–6.
83. Sareen J, Cox BJ, Affifi T et al. Anxiety disorders and risk of suicidal ideation and suicide attemps: a population based, longitudinal study of adults. Arch Gen Psychiatr 2005; 62: 1249–57.
84. Skre I, Onstad S, Evardsen J et al. A family study of generalized anxiety disorder: familial transmission and relationship to mood disorder. Acta Psychiatr Scand 1994; 90: 366–74.
85. Skre I, Onstad S, Torgersen S et al. A twin study of DSM-IIIR anxiety disorder. Acta Psychiatr Scand 1993; 88: 85–92.
86. Smith W, Targum S, Feltner DE et al. Pregabalin in GAD: long term efficacy and relapse prevention. Eur Neuropsychopharmacol 2002; 12 (Suppl. 3): 350.
87. Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory GAD. J Clin Psychopharmacol 2005; 25 (5): 497–8.
88. Spitzer R, Kroenke K, Williams J et al. A brief measure for assessing generalized anxiety disorder. Arch Int Med 2006; 166: 1092–7.
89. Stahl SM. Anticonvulsants as anxiolytics: Part 2 Pregabalin and gabapentin as alpha2delta ligands at voltage gated calcium channels. J Clin Psychiatry 2004; 65: 460–1.
90. Stein MB, Heimberg RG. Well-being and life satisfaction in GAD: comparison to major depressive disorder in a community sample. J Affect Dis 2004; 79: 161–6.
91. Taylor CP. The biology and pharmacology of calcium channel proteins. CNS Drug Rev 2004; 10: 183–8.
92. Taylor DP, Eison MS, Riblet LA et al. Pharmacological and clinical effects of buspirone. Pharmacol Biochem Bahav 1985; 23: 687–94.
93. Terrie E, HonaLee H, Avshalom C et al. Depression and generalized anxiety disorder: cumulative and sequental comorbidity in a Birth cohort followed prospectively to age 32 years. Arch Gen Psychiatry 2007; 64 (6): 651–60.
94. Ustun TB, Sartorius N. Mental illness in general health care. An International Study. WHO, Wiley&Sons, 1995.
95. Van Praag HM. Anxiety and increased aggression as pacemakers of depression. Acta Psychiatr Scand 1998; 98 (Suppl. 393): 81–8.
96. Wang PS, Berglund P, Kessler RC. Recent care of common mental disorders in the United States. J Gen Intern Med 2000; 15 (5): 284–92.
97. Wise MG, Taylor SE. Anxiety and mood disorders in medically ill patients. J Clin Psychiatry 1990; 51 (1): 27–32.
98. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-IIIR generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 355–64.
99. Wittchen HU. Recognition and management of anxiety symptoms. Brit J Psychiatr 1998; 173 (Suppl. 34): 1–3.
100. Wittchen HU. Generalized anxiety disorder: prevalence, burden and cost to society. Depress Anxiety 2002; 16 (4): 162–71.
101. Wittchen HU. Generalized anxiety disorder – a risk factor for depression? Int J Met Psych Res 2006; 10 (1): 52–7.
102. Wittchen HU, Carter RM, Pfister H et al. Disabilities and quality of life in pure and comorbid GAD and major depression in a national survey. Int Clin Psychopharmacol 2000; 15: 319–28.
103. Wu JC. Buchsbaum MS, Hershey TG et al. PET in generalized anxiety disorder. Biol Psychiatry 1991; 29: 1181–9.
104. Yonkers KA, Dyck IR, Warshaw M et al. Factors predicting the clinical course of GAD. Br J Psychiatr 2000; 176: 544–9.
105. Yonkers KA, Bruce SE, Dyck IR et al. Chronicity, relapse and illness: course of panic disorder, social phobia and GAD. Depres Anxiety 2003; 17 (3): 173–9.

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

Генерализованное тревожное расстройство: эпидемиология, патогенез, диагностика и фармакотерапия (обзор литературы)

Материал для специалистов

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

Генерализованное тревожное расстройство: эпидемиология, патогенез, диагностика и фармакотерапия (обзор литературы)

Материал для специалистов

Con-Med Passport